BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: April 9

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.

  April 9, 2020

   · 

  9 min read

   · 

  BioSpace Editorial Staff
• 

  Pharm Country

  Pfizer Advances BioNTech COVID-19 Program and Plans Clinical Trials for Potential Treatments

  Pfizer and BioNTech updated their development program, with plans to launch clinical trials in the U.S. and Europe across multiple sites by the end of April.

  April 9, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Signals Analytics Launches COVID-19 Playbook Analytics Platform to Accelerate Vaccine and Drug Development

  If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.

  April 9, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  BioMidwest

  American Lung Association Launches $25 Million Fund to Fight COVID-19, Future Pandemics

  Anyone who breathes is at risk for contracting COVID-19, the disease caused by the novel coronavirus, and the estimated 36 million Americans who have lung diseases are even more at risk for developing severe complications related to the disease.

  April 9, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  All Eyes on Gilead’s Readout of Remdesivir for COVID-19

  Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.

  April 9, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biotech Beach Emergent BioSolutions Aims to Fight COVID-19

  Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.

  April 9, 2020

   · 

  2 min read

   · 

  Gail Dutton
• 

  Business

  BioSpace Movers & Shakers, April 10

  Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.

  April 9, 2020

   · 

  6 min read

   · 

  Alex Keown
• 

  Business

  Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck

  Rexahn said it notified Merck on April 7 of its decision to discontinue the development of RX-5902 for the treatment of metastatic triple-negative breast cancer.

  April 9, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  Research Roundup: COVID-19 Lockdown’s Impact on Mental Health and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  April 9, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  FDA

  FDA Approves Pfizer’s Braftovi Plus Cetuximab for Colorectal Cancer with BRAF Mutations

  “We are pleased by the FDA’s approval of Braftovi in combination with cetuximab, as we are committed to developing targeted medicines that can help people living with certain mutation-driven cancers,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.

  April 9, 2020

   · 

  2 min read

   · 

  Mark Terry